Gland Pharma lists at 14% premium over issue price
The IPO, which was sold between November 9 and 11, was subscribed 2.06 times in a three-day bidding process, with the HNI and retail quotas undersubscribed.from Markets-Economic Times https://ift.tt/3lStA9q
Post a Comment